Tumores Torácicos

Estudo randomizado | Nivolumabe neoadjuvante com quimioterapia no câncer ressecável de pulmão.

14 Abr, 2022 | 16:46h

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer – New England Journal of Medicine

Comunicado de imprensa: Immunotherapy Plus Chemotherapy Before Surgery Improves Outcomes for Patients with Lung Cancer – Johns Hopkins Medicine

 

Comentário no Twitter

In patients with resectable NSCLC, neoadjuvant nivolumab plus chemo results in longer event-free survival and a greater likelihood of pathological complete response than chemo alone. #AACR22 https://t.co/ILjdRZQ7dJ pic.twitter.com/1JfiUw18R6

— NEJM (@NEJM) April 11, 2022

 

---

Estudo quase experimental | Associação do rastreamento por tomografia computadorizada com mudança de estágio do câncer de pulmão no diagnóstico e sobrevida.

1 Abr, 2022 | 12:21h

Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study – The BMJ

Editorial: Screening high risk populations for lung cancer

Comunicado de imprensa: US lung cancer screening linked to earlier diagnosis and better survival – British Medical Journal

Conteúdos relacionados:

Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk

Meta-analysis: Lung cancer screening using low-dose computed tomography reduces lung cancer–specific mortality, albeit with a tradeoff of likely overdiagnosis

 

Comentário no Twitter

Increases in the early detection of lung cancer since 2014 in the US have saved an estimated 10,100 lives, but screening rates are still extremely low and disparities in access to lung cancer screening continue to exist, say researchers https://t.co/j58LfcGCKU

— The BMJ (@bmj_latest) March 31, 2022

 

---

Estudo multicêntrico de acurácia comparativa | Tomografia computadorizada dinâmica com contraste vs. tomografia por emissão de pósitrons para caracterizar nódulos pulmonares solitários.

16 Mar, 2022 | 17:32h

Resumo: Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling – Health Technology Assessment

Download: Full Report

---

Revisão | Indicações cirúrgicas atuais para câncer pulmonar de não pequenas células.

11 Mar, 2022 | 14:35h

Current Surgical Indications for Non-Small-Cell Lung Cancer – Cancers

---

Estudo randomizado | Função da ultrassonografia torácica no seguimento da pleurodese para derrames pleurais malignos.

8 Mar, 2022 | 18:12h

Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial – The Lancet Respiratory Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

Thoracic ultrasonography-guided pleurodesis in patients with malignant pleural effusions results in shorter hospital stay without reducing the success rate of the procedure at 3 monthshttps://t.co/hof4Rd2nUt

— K Pavithran (@drkpavithran) March 2, 2022

 

---

Estudo randomizado | Em pacientes com câncer de pulmão em estágio inicial, lobectomia toracoscópica vídeo-assistida está associada com melhor recuperação da função física em 5 semanas em comparação com cirurgia aberta.

3 Mar, 2022 | 16:36h

Video-Assisted Thoracoscopic or Open Lobectomy in Early-Stage Lung Cancer – NEJM Evidence

 

Comentário no Twitter

For patients with early-stage #LungCancer, resection by video-assisted thoracoscopic surgery was superior to open resection with respect to postoperative recovery of physical function as shown in a randomized trial. @ekslim @RBandH #VATS #OncoAlert https://t.co/j23CgZp5U5 pic.twitter.com/UsIx3D8Zem

— NEJM Evidence (@NEJMEvidence) January 19, 2022

 

---

Diretrizes clínicas do SEOM-GECP-GETTHI para o tratamento de pacientes com tumores epiteliais tímicos.

3 Mar, 2022 | 15:34h

SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021) – Clinical and Translational Oncology

---

Atualização de diretriz ASCO | Terapia sistêmica adjuvante e radioterapia adjuvante para câncer de pulmão de não pequenas células estágios I-IIIA completamente ressecado.

24 Fev, 2022 | 13:39h

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

Comentário: Rapid Guideline Revises Recommendations for Adjuvant Therapy in Patients With Early-Stage Lung Cancer – ASCO Daily News

 

Comentário no Twitter

‼️ Just published in #JCO: @ASCO rapid guideline update on adjuvant systemic therapy & adjuvant radiation therapy for stage I to IIIA completely resected #NSCLC 🫁 https://t.co/OheQi7Bi97 #lcsm #radonc pic.twitter.com/Dax2orUXZy

— Journal of Clinical Oncology (@JCO_ASCO) February 15, 2022

 

---

Diretriz de prática clínica em oncologia da NCCN | Câncer pulmonar de pequenas células, versão 2.2022.

7 Fev, 2022 | 13:38h

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

---

Desfechos de sobrevida de 5 anos do PACIFIC Trial: durvalumabe pós-quimioradioterapia no câncer de pulmão não pequenas células estágio III.

4 Fev, 2022 | 17:15h

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer – Journal of Clinical Oncology

Estudo original: Randomized Trial: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

---